A61K 47/62
The modifying agent being a protein, peptide or polyamino acid
Official title: the modifying agent being a protein, peptide or polyamino acid
A61K47/62 (The modifying agent being a protein, peptide or polyamino acid) appears on 7,345 US grants and 12,260 published applications in this corpus.
Search patents in A61K- Granted patents
- 7,345
- Published applications
- 12,260
- Assignees
- 3,943
- Inventors
- 19,873
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 2 | 0 |
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 2 | 0 |
| 1981 | 3 | 0 |
| 1982 | 9 | 0 |
| 1983 | 4 | 0 |
| 1984 | 3 | 0 |
| 1985 | 5 | 0 |
| 1986 | 5 | 0 |
| 1987 | 5 | 0 |
| 1988 | 9 | 0 |
| 1989 | 18 | 0 |
| 1990 | 9 | 0 |
| 1991 | 24 | 0 |
| 1992 | 41 | 0 |
| 1993 | 37 | 0 |
| 1994 | 51 | 0 |
| 1995 | 59 | 0 |
| 1996 | 52 | 0 |
| 1997 | 89 | 0 |
| 1998 | 124 | 0 |
| 1999 | 113 | 0 |
| 2000 | 117 | 0 |
| 2001 | 127 | 31 |
| 2002 | 135 | 197 |
| 2003 | 101 | 329 |
| 2004 | 97 | 327 |
| 2005 | 91 | 296 |
| 2006 | 148 | 295 |
| 2007 | 125 | 247 |
| 2008 | 125 | 292 |
| 2009 | 129 | 321 |
| 2010 | 155 | 386 |
| 2011 | 174 | 363 |
| 2012 | 162 | 351 |
| 2013 | 223 | 367 |
| 2014 | 287 | 485 |
| 2015 | 320 | 540 |
| 2016 | 336 | 605 |
| 2017 | 387 | 531 |
| 2018 | 364 | 604 |
| 2019 | 385 | 706 |
| 2020 | 432 | 758 |
| 2021 | 419 | 760 |
| 2022 | 397 | 773 |
| 2023 | 397 | 742 |
| 2024 | 411 | 784 |
| 2025 | 400 | 694 |
| 2026 | 236 | 476 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Drug containing targeting liposomes6 Oct 2026US 12,752,016 B2Nextage Therapeutics Ltd.
- Bifunctional molecules for lysosomal targeting and related compositions and methods6 Oct 2026US 12,753,239 B2The Board of Trustees of the Leland Stanford Junior University
- Antibody conjugates and uses thereof6 Oct 2026US 12,753,242 B2GlycoNex Inc.
- Bimetallic fluorescent nanocomposites for cancer theranostics29 Sep 2026US 12,746,598 B2Council of Scientific and Industrial Research
- Liquid formulation22 Sep 2026US 12,741,011 B2Hanmi Pharm. Co., Ltd.
- Antibody recruiting molecules for the treatment of coronavirus disease-198 Oct 2026US 2026/0306644 A1Biohaven Therapeutics Ltd.
- Modular platform for molecular conjugation8 Oct 2026US 2026/0306645 A1CamBrixBio Ltd
- Targeted lipid nanoparticles for treating central nervous system injuries8 Oct 2026US 2026/0306665 A1Wisconsin Alumni Research Foundation
- Pharmaceutical composition for treatment of cancer, comprising an immune checkpoint inhibitor antibody and a fusion protein comprising an il-2 mutant and a cd80 extracellular domain8 Oct 2026US 2026/0308251 A1Gi Innovation, Inc.
- A proimmunotoxin therapeutic nanoplatform against cancer8 Oct 2026US 2026/0308268 A1The Regents of the University of California
Most cited
By later US patents
- Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers896US 5,410,016 ABoard of Regents, The University of Texas System · 1995
- Collagen-polymer conjugates778US 5,162,430 ACollagen Corporation · 1992
- Gels for encapsulation of biological materials587US 5,858,746 ABoard of Regents, The University of Texas System · 1999
- Cationic lipids for intracellular delivery of biologically active molecules586US 5,459,127 AVical Incorporated · 1995
- Cationic lipids for intracellular delivery of biologically active molecules545US 5,264,618 AVical Incorporated · 1993